GENETIC CHANGES AND HISTOPATHOLOGICAL GRADES IN HUMAN HEPATOCELLULAR CARCINOMAS

被引:74
作者
KONISHI, M
KIKUCHIYANOSHITA, R
TANAKA, K
SATO, C
TSURUTA, K
MAEDA, Y
KOIKE, M
TANAKA, S
NAKAMURA, Y
HATTORI, N
MIYAKI, M
机构
[1] TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,3-18-22 HONKOMAGOME,BUNKYO KU,TOKYO 113,JAPAN
[2] TOKYO METROPOLITAN KOMAGOME HOSP,DEPT INTERNAL MED,BUNKYO KU,TOKYO 113,JAPAN
[3] TOKYO METROPOLITAN KOMAGOME HOSP,DEPT SURG,BUNKYO KU,TOKYO 113,JAPAN
[4] TOKYO METROPOLITAN KOMAGOME HOSP,DEPT PATHOL,BUNKYO KU,TOKYO 113,JAPAN
[5] JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1993年 / 84卷 / 08期
关键词
HEPATOCELLULAR CARCINOMA; LOH; P53; MUTATION; HISTOPATHOLOGICAL DIAGNOSIS; HEPATITIS VIRUS INFECTION;
D O I
10.1111/j.1349-7006.1993.tb02063.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Loss of heterozygosity (LOH) on chromosomes 1p, 4q, 5q, 8p, 13q, 16q, 17p, and 22q, and mutation of the p53 gene were simultaneously analyzed in 63 hepatocellular carcinomas (HCCs) with distinct histopathological grades, 80% of the tumors being from patients who had been exposed to hepatitis B virus (HBV) or hepatitis C virus (HCV). The frequencies of LOH on 8 chromosomes were 0-25% in 10 well differentiated HCCs, LOH being observed on 4q, 5q and 17p, 21-53% in 26 moderately differentiated HCCs, LOH on 8p and 17p being high, and 29-75% in 27 poorly differentiated HCCs, LOH on 17p, 4q and 8p being the most frequent. p53 gene mutation was detected in moderately and poorly differentiated HCCs at 15% and 52%, respectively, but not at all in well differentiated HCCs. Of the mutations detected, 42% were transition mutation and only 5% were CpG transition, in contrast to the high frequencies of these types of mutations in colon tumors (78% and 54%, respectively). LOH on every chromosome and p53 mutation were more frequent in more advanced tumors, and accumulation of genetic changes increased with increase of the histopathological grade. Frequency of genetic changes in HCCs from HBV-positive patients was comparable to that from HCV-positive patients. The present results suggest that accumulation of genetic changes in multiple tumor suppressor genes, especially LOH on 17p, 4q and 8p, and mutation in p53 gene, are involved in the progression of liver cancer, and LOH on 17p and 4q precedes other genetic changes. Differences in the direction of p53 mutation between HCC and colon carcinoma suggest that liver carcinogens are distinct from colon carcinogens. Furthermore, mechanisms affecting the frequency of LOH in HCCs in HBV-infected patients may be similar to those in HCV-infected patients.
引用
收藏
页码:893 / 899
页数:7
相关论文
共 41 条
[1]   ONCOGENE ACTIVATION IN CHEMICAL CARCINOGENESIS [J].
BALMAIN, A ;
BROWN, K .
ADVANCES IN CANCER RESEARCH, 1988, 51 :147-182
[2]  
BEASLEY RP, 1981, LANCET, V2, P1129
[3]   PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].
BOS, JL ;
FEARON, ER ;
HAMILTON, SR ;
VERLAANDEVRIES, M ;
VANBOOM, JH ;
VANDEREB, AJ ;
VOGELSTEIN, B .
NATURE, 1987, 327 (6120) :293-297
[4]   SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA [J].
BRESSAC, B ;
KEW, M ;
WANDS, J ;
OZTURK, M .
NATURE, 1991, 350 (6317) :429-431
[5]   LOSS OF HETEROZYGOSITY SUGGESTS TUMOR SUPPRESSOR GENE RESPONSIBLE FOR PRIMARY HEPATOCELLULAR-CARCINOMA [J].
BUETOW, KH ;
MURRAY, JC ;
ISRAEL, JL ;
LONDON, WT ;
SMITH, M ;
KEW, M ;
BLANQUET, V ;
BRECHOT, C ;
REDEKER, A ;
GOVINDARAJAH, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8852-8856
[6]   A HIGHLY POLYMORPHIC LOCUS ON CHROMOSOME-16Q REVEALED BY A PROBE FROM A CHROMOSOME-SPECIFIC COSMID LIBRARY [J].
BUFTON, L ;
MOHANDAS, TK ;
MAGENIS, RE ;
SHEEHY, R ;
BESTWICK, RK ;
LITT, M .
HUMAN GENETICS, 1986, 74 (04) :425-431
[7]  
CAVENEE W, 1984, AM J HUM GENET, V36, P10
[8]   HEPATOCELLULAR-CARCINOMA [J].
DIBISCEGLIE, AM ;
RUSTGI, VK ;
HOOFNAGLE, JH ;
DUSHEIKO, GM ;
LOTZE, MT .
ANNALS OF INTERNAL MEDICINE, 1988, 108 (03) :390-401
[9]  
EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO
[10]  
2-E